Author | OncLive Staff | OncLive

Author | OncLive Staff


FDA Approval Insights: Ramucirumab/Erlotinib in EGFR+ Metastatic NSCLC

July 06, 2020


Edgardo S. Santos, MD, discusses the data that led to the approval of the combination of ramucirumab and erlotinib in EGFR-mutant metastatic non–small cell lung cancer and shared his thoughts on its utility in the frontline setting.

Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon

July 02, 2020


In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.

Research Reflections: Weinberg Weighs in on Thought-Provoking Data in CRC

June 29, 2020


Benjamin Weinberg, MD, shares the clinical implications of how data from the 2020 ASCO Virtual Scientific Program may impact in the treatment of patients with colorectal cancer and projects what the future may hold in the space.

FDA Approval Insights: Olaparib in HRR-Mutant mCRPC

June 25, 2020


In our exclusive interview, Neeraj Agarwal, MD, discusses the recent FDA approval of olaparib in homologous recombination repair–mutant metastatic castration-resistant prostate cancer.